Skip to main content
Figure 2 | Journal of Hematology & Oncology

Figure 2

From: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Figure 2

Durations of response for patients who achieved CR/CRu on romidepsin (investigator assessed; n = 21). Only investigators assessed DOR for prior therapy (for patients with PR or CR on prior therapy). Arrows indicate that the patient was censored while in response. * Indicates that the patient received combination chemotherapy as the last prior therapy. NR indicates that the response to prior therapy was not reported.

Back to article page